financetom
Business
financetom
/
Business
/
Vale reports second board exit in four months amid CEO search
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Vale reports second board exit in four months amid CEO search
Jul 1, 2024 4:11 PM

RIO DE JANEIRO, July 1 (Reuters) - Brazilian miner Vale

has lost its second board member in less than four

months, it said in a filing on Monday, reporting the resignation

of Vera Marie Inkster.

Vale, which is in the process of looking for a new CEO, gave

no reason for Inkster's resignation in the filing.

In March, Jose Luciano Duarte Penido also left the board of

directors, saying in his resignation letter, seen by Reuters at

the time, that the firm's succession process was being conducted

in a "manipulated manner."

Days before Penido's exit, Vale had extended the term of

Chief Executive Eduardo Bartolomeo until the end of the year,

amid media reports that the Brazilian government was seeking to

influence the choice of a new CEO.

Although Vale was privatized over 25 years ago, the

government has continued to exert pressure on the miner's board

of directors at times through public-sector pension funds.

Penido was favorable to fully renewing Bartolomeo's term,

Reuters reported at the time, citing a source.

As Inkster and Penido were both independent board members,

Monday's exit should trigger Vale to call for a shareholders

meeting, as the number of independent members is now below the

seven defined by the miner's bylaws.

In the filing on Monday, Vale said the board will call a

meeting "in due course."

The company declined to provide further comment when

requested by Reuters.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cipher Pharmaceuticals Acquires Head Lice, Scabies Treatment Products from ParaPRO for US$89.5 Million
Cipher Pharmaceuticals Acquires Head Lice, Scabies Treatment Products from ParaPRO for US$89.5 Million
Jul 29, 2024
07:39 AM EDT, 07/29/2024 (MT Newswires) -- Cipher Pharmaceuticals ( CPHRF ) on Monday said it has signed an agreement with ParaPRO to acquire the global product rights for head lice and scabies treatment Natroba (and authorized generic Spinosad), and the 50-person commercial sales team in the U.S. for US$89.5 million. Cipher paid US$80 million in cash, and issued US$9.5...
Collective Mining Reports Latest Assays from Trap Target in Colombia
Collective Mining Reports Latest Assays from Trap Target in Colombia
Jul 29, 2024
07:38 AM EDT, 07/29/2024 (MT Newswires) -- Collective Mining ( CNL ) reported Monday assays for four holes drilled at the Trap target near the Apollo system within the company's Guayabales project in Colombia. Highlights include 40.85 meters at 3.76 grams per tonne (g/t) gold equivalent within 174.45 meters at 1.19 gold equivalent. The company said the Trap target can...
Pearson Interim H1 Adjusted Earnings Flat, Revenue Declines; Reaffirms Outlook
Pearson Interim H1 Adjusted Earnings Flat, Revenue Declines; Reaffirms Outlook
Jul 29, 2024
07:39 AM EDT, 07/29/2024 (MT Newswires) -- Pearson (PSO) reported H1 interim adjusted earnings Monday of 25.6 pence ($3.29) per share, unchanged from a year earlier. Revenue for the six months ended June 30 was 1.75 billion pounds compared with 1.88 billion pounds a year earlier. Pearson reaffirmed its 2024 sales growth, adjusted operating profit, and tax outlook. The educational...
GSK Settles Zantac Case With Ronald Kimbrow
GSK Settles Zantac Case With Ronald Kimbrow
Jul 29, 2024
07:35 AM EDT, 07/29/2024 (MT Newswires) -- GSK (GSK) said Monday that it reached a confidential settlement with Ronald Kimbrow to resolve the Zantac case he filed in Illinois state court. The company said it does not admit liability, and the case regarding GSK will be dismissed. Based on 16 epidemiological studies, GSK said there is no consistent or reliable...
Copyright 2023-2026 - www.financetom.com All Rights Reserved